Clinical trials: Acute Myocardial Infarction (AMI)
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
ST-Segment Elevation Myocardial Infraction
IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction
Myocardial Infarctions (MI) are commonly known as heart attacks. An ST-Segment Elevation Myocardial Infarction (STEMI) is a more severe type of heart attack.
- Trial name
- NCT01007461
- Testing
- Sodium Sulfide (Na2S) for Injection
- Sponsor
- Mallinckrodt
Myocardial Infarction
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
The purpose of this study is to determine whether prompt removal of thrombus (blood clot) from a blocked coronary artery using the AngioJet rheolytic thrombectomy device will result in improved blood flow within the heart and a…
- Trial name
- NCT00275990
- Testing
- rheolytic thrombectomy with direct stenting, direct stenting
- Where
- Italy
- Volunteers
- 501 people
- Sponsor
- Boston Scientific Corporation
Acute Myocardial Infarction, ST Elevation Myocardial Infarction
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
The objective of this study is to evaluate the safety and tolerability of two active doses of RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial infarction receiving percutaneous coronary…
- Conditions
- Acute Myocardial Infarction, ST Elevation Myocardial Infarction, STEMI
- Trial name
- NCT01311518
- Testing
- Drug: Injectable Thymosin beta 4
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
AMI Cardiogenic Shock
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
The observational study titled "Observational Assessment of Support with Impella Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock (OASIS-AMICS)" aims to evaluate the safety outcomes of patients with…
- Trial name
- OASIS-AMICS (NCT06964685)
- Testing
- Impella
- Where
- 21 sites in United States
- Volunteers
- 350 people
- Sponsor
- Abiomed Inc.
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Acute Coronary Syndromes
Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms
Study Objectives The following items will be prospectively assessed. Primary Endpoints 1. For patients presenting with clinical suspicion of Acute Coronary Syndromes (ACS), high sensitivity-cardiac Troponin I (hs-cTnI) provides…
- Trial name
- FAST-TRAC (NCT00880802)
- Where
- 16 sites in United States, Greece and 2 more
- Volunteers
- 1,500 people
- Sponsor
- Nanosphere, Inc.
Acute Myocardial Infarction
Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)
Double blind, prospective, randomized, placebo-controlled Safety and Efficacy trial of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (STEMI).
- Trial name
- ADVANCE (NCT01216995)
- Testing
- Dose A
- Where
- 4 sites in Netherlands, Poland
- Volunteers
- 23 people
- Sponsor
- Cytori Therapeutics
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.
Acute Coronary Syndrome, Myocardial Infarction
Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients
Genetesis is a cardiac diagnostics company which presents a novel magnetocardiogram (MCG) analysis system called CardioFlux. This investigation presents a new, noninvasive diagnostic option to use MCG for rapid diagnosis of acute…
- Trial name
- NCT03255772
- Testing
- Magnetocardiography
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Genetesis Inc.
Acute Myocardial Infarction
STEMI Cool Pilot Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
A Multicenter, Prospective, Randomized-Controlled Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention In Patients with Acute Myocardial Infarction.
- Trial name
- STEMI Cool (NCT03361995)
- Testing
- Cooling Procedure using the ZOLL Thermogard XP3 IVTM System, PCI
- Sponsor
- ZOLL Circulation, Inc., USA
Cardiogenic Shock, Acute Decompensated Heart Failure
SURPASS Impella 5.5 Study
A multi-center, prospective \& retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of…
- Trial name
- NCT05100836
- Testing
- Impella 5.5
- Where
- 15 sites in United States
- Volunteers
- 1,017 people
- Sponsor
- Abiomed Inc.
Acute Coronary Syndrome
Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain
The purpose of this study is to evaluate if the implementation of quantitative pretest probability assessment will significantly reduce the unnecessary use of the intra-emergency department chest pain center.
- Trial name
- NCT00243516
- Testing
- PREtest Consult
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- PREtest Consult
Acute Myocardial Infarction
To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
Through the injection of Hearticellgram-AMI into acute myocardial infarction patients who are the primary targets of the drug, long term efficacy in the improvement of the left ventricle ejection fraction upon the first cell…
- Trial name
- NCT01652209
- Testing
- Hearticellgram-AMI
- Where
- 10 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Pharmicell Co., Ltd.
Myocardial Infarction
Safety and Efficacy Study of MGuard Stent After a Heart Attack
The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the…
- Trial name
- MASTER (NCT01368471)
- Testing
- MGuard, Control BMS or DES
- Where
- 7 sites in Poland, South Africa
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- InspireMD
Acute Myocardial Infarction
A Trial Using Double-Bolus THR-100 Versus Streptokinase
This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some strains of Staphylococcus aureus and readily produced by recombinant DNA technology.
- Trial name
- THR-100 (NCT01305226)
- Testing
- THR-100, Streptokinase
- Where
- 4 sites in India
- Volunteers
- 120 people
- Sponsor
- Bharat Biotech International Limited